Researchers characterize production process for standardized monoclonal antibody

Researchers at the Institute for Bioscience and Biotechnology (IBBR) in Maryland in the U.S. have taken the first step towards developing a method for the production of a standardized monoclonal antibody (mAb).

HeLa cells©EnCor Biotechnology Inc

Study author Zvi Kelman says that by developing a way of producing the antibody, called NISTmAb, they can make the measurements that will define the production process.

Monoclonal antibodies are synthesized proteins that are designed to specifically target diseased cells, pathogens and other antigens for removal from the body. They are also used to deliver dugs or radiation to specific sites in the body.

The drugs have had an astonishing impact on medicine and today five of the ten most commonly sold pharmaceuticals are mAbs.

As patents on these mAbs expire in years to come, many biopharmaceutical companies will want to release generic versions (called biosimilars) of the original mAbs.

Both the manufacturers and FDA regulators of the biosimilars must confirm that they match the originals in terms of effectiveness, quality and safety.

In July 2016, the National Institute of Standards and Technology, issued the world’s first standardized mAb which was intended to help verify the quality of measurement techniques used in the development of biologics for a wide range of health conditions.

While the drug itself has been well characterized, the proprietary method used to produce it has not.

As reported in the journal mAbs, the IBBR researchers have now engineered three cell lines to produce non-propriety versions of mAb that closely match the characteristics of the original drug.

Having a rigorously characterized mAb production process, along with our standard NISTmAb protein, will serve as powerful benchmarking tools that should help manufacturers and regulators release new mAb therapeutics and biosimilars with greater confidence."

John Marino, Co-author

Source

https://www.eurekalert.org/pub_releases/2018-07/nios-ncl073118.php

Sally Robertson

Written by

Sally Robertson

Sally has a Bachelor's Degree in Biomedical Sciences (B.Sc.). She is a specialist in reviewing and summarising the latest findings across all areas of medicine covered in major, high-impact, world-leading international medical journals, international press conferences and bulletins from governmental agencies and regulatory bodies. At News-Medical, Sally generates daily news features, life science articles and interview coverage.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Researchers characterize production process for standardized monoclonal antibody. News-Medical. Retrieved on July 14, 2020 from https://www.news-medical.net/news/20180801/Researchers-characterize-production-process-for-standardized-monoclonal-antibody.aspx.

  • MLA

    Robertson, Sally. "Researchers characterize production process for standardized monoclonal antibody". News-Medical. 14 July 2020. <https://www.news-medical.net/news/20180801/Researchers-characterize-production-process-for-standardized-monoclonal-antibody.aspx>.

  • Chicago

    Robertson, Sally. "Researchers characterize production process for standardized monoclonal antibody". News-Medical. https://www.news-medical.net/news/20180801/Researchers-characterize-production-process-for-standardized-monoclonal-antibody.aspx. (accessed July 14, 2020).

  • Harvard

    Robertson, Sally. 2018. Researchers characterize production process for standardized monoclonal antibody. News-Medical, viewed 14 July 2020, https://www.news-medical.net/news/20180801/Researchers-characterize-production-process-for-standardized-monoclonal-antibody.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.